Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Express News | Arcutis Announces Health Canada Approval of Zoryve® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $19
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating